$11.87
3.50% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US67576A1007
Symbol
OCUL

Ocular Therapeutix Inc Stock price

$11.87
-0.34 2.78% 1M
+5.10 75.33% 6M
+3.33 38.99% YTD
+2.86 31.74% 1Y
+6.33 114.26% 3Y
+3.28 38.18% 5Y
-5.32 30.95% 10Y
-1.28 9.73% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.43 3.50%
ISIN
US67576A1007
Symbol
OCUL
Industry

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.7b
Net debt
positive
Cash
$391.1m
Shares outstanding
172.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
36.5 | 36.9
EV/Sales
30.8 | 31.2
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
68.9%
Return on Equity
-61.4%
ROCE
-55.9%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$56.7m | $56.0m
EBITDA
$-224.2m | $-257.9m
EBIT
$-228.1m | $-252.0m
Net Income
$-216.8m | $-269.7m
Free Cash Flow
$-179.4m
Growth (TTM | estimate)
Revenue
-7.3% | -12.2%
EBITDA
-80.1% | -53.5%
EBIT
-77.9% | -46.7%
Net Income
-56.6% | -39.4%
Free Cash Flow
-98.0%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-395.7% | -460.8%
EBIT
-402.6%
Net
-382.5% | -481.9%
Free Cash Flow
-316.5%
More
EPS
$-1.3
FCF per Share
$-1.0
Short interest
7.5%
Employees
274
Rev per Employee
$230.0k
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
94%
Hold
6%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
57 57
7% 7%
100%
- Direct Costs 6 6
7% 7%
11%
51 51
9% 9%
89%
- Selling and Administrative Expenses 107 107
20% 20%
189%
- Research and Development Expense 172 172
113% 113%
304%
-224 -224
80% 80%
-396%
- Depreciation and Amortization 3.92 3.92
5% 5%
7%
EBIT (Operating Income) EBIT -228 -228
78% 78%
-403%
Net Profit -217 -217
57% 57%
-383%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
The Motley Fool
20 days ago
Ocular Therapeutix (OCUL -2.83%), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments.
Neutral
Seeking Alpha
21 days ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.
Neutral
GlobeNewsWire
about one month ago
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today